Centro De Ingenieria Genetica Y Biotecnologia

Leonardo Canan-Haden Frias

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Luis Saturnino Herrera Martinez

Haydee Geronimo Perez

Jose Ignacio Fernandez Montequin

Ingrid Rojas Constantin

Hector Santana Milian

Jorge Sotolongo Pena

Neobalis Franco Perez

Larissa Chacon Corvea

Calixto Valdes Perez

Jose I Fernandez Montequin

The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention

Growing community of inventors

Ciudad de la Habana, Cuba

Leonardo Canan-Haden Frias